Impact of Levetiracetam and Valproic Monotherapy in Quality of Life in Patients With Epilepsy

Home
IMPACT OF LEVETIRACETAM AND VALPROIC MONOTHERAPY IN

QUALITY OF LIFE IN PATIENTS WITH EPILEPSY
Epilepsy is a common neurological disorder with annual incidence of
epilepsy in world population is 50/100000 and that in the Indian
population is 27.3 per 100000 with prevalence of 5.59 per 1000. 1
Quality of life plays an important role in patients of epilepsy and is the
most neglected part during management. Adverse effects of drugs also
play a major role in ensuring quality of life in epilepsy patients along
with the effects of epilepsy. However, newer antiepileptic drug
(AEDs) with their better safety profile hold an edge over the
conventional AEDs.2
OBJECTIVE2
☐ To compare valproic acid and levetiracetam as monotherapy for
comparison of quality of life in patients with generalized tonic
clonic seizure (gtcs) epilepsy
STUDY DETAILS2
☐ Design: observational analytical study
☐ Patient details: patient ages 18-60 years, diagnosed with GTCS and who were stabilized on their
respective drug dosage for more than 1.5 months or less than 4.5 months
☐ Study comparators/ intervention used: Levetiracetam (LEV) 500- 2000mg/day and for Valproic acid
(VPA) 300-1000mg/day; quality of life was assessed using Quality of life in Epilepsy (QOLIE-10)
questionnaire
☐ Follow-up duration: 12 months
Updated on 22nd September 2020
2
KEY RESULTS
☐ Total 85 patients were enrolled out of which 41 were in the LEV group and 44 in the VPA group
☐ The baseline QOLIE- 10 score in LEV group for epilepsy effect, mental effect and role function
effect was 10.37±0.99, 10.22±1.06 and 13.83±0.97 respectively which was later reduced to
5.10±1.04, 4.83±0.97, 6.39±0.95 after 12 weeks.
☐ The difference of QOLIE-10 score between the group at the end of 12 week for epilepsy effect in
LEV and VPA group was 5.25±1.18 and 3.07±1.73 (p=0.051) respectively; for mental effects in
LEV and VPA was 5.39±1.20 and 3.39±1.82 (p=0.023)respectively and for role function effect in
LEV and VPA was 7.44±1.42 and 4.75±2.17 (p=0.017) respectively
☐ Study drugs showed significant improvement in quality of life, levetiracetam showed mean change
that was significantly greater than valproic acid (p=0.003) at 12 weeks
☐ Patients who failed to achieve seizure control at 6 weeks were 17% patients in levetiracetam and
20% in valproic acid group, reason being non-adherence which was 17% and 20% respectively
☐ Adverse events recorded with Levetiracetam (10), most common being increased sleep and with
valproic acid (18), with most common being increased sleep and weight gain
For the use of Registered Medical Practitioners, Hospital or Laboratory only.
Reference:
1) Banerjee T et al. A longitudinal study of epilepsy in Kolkata, India. Epilepsia. 2010; 51(12): 2384-94
2) Verma SK et2
CONCLUSION al. Evaluation of levetiracetam and valproic acid as monotherapy on quality of life in
patients of generalized tonic clonic epilepsy. IJBCP. 2020: 4(7); 669- 675
Levetiracetam treatment results in better quality of life, with similar seizure control but decreased
number of adverse effect then Valproic acid
The scientific content shared via this email is medically validated excerpts, solely for knowledge upgradation and informational purposes. Cipla makes every
effort to present accurate and reliable information, but does not endorse, warrant, or assume any legal liability or responsibility for, the accuracy or
completeness of any information provided. Any change in the treatment regime is totally in discretion of the physician. No part of this may be reproduced,
transmitted or stored in any form or by any means either mechanically or electronically without prior intimation to Cipla.
*Dear Doctor,
The above content has been shared on your request. We retain your right to revoke this consent at any time by informing
Cipla Limited of the same in writing or by simply clicking on unsubscribe.

Impact of Levetiracetam and Valproic Monotherapy in Quality of Life in Patients With Epilepsy

Uploaded by

Copyright:

Available Formats

Impact of Levetiracetam and Valproic Monotherapy in Quality of Life in Patients With Epilepsy

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Impact of Levetiracetam and Valproic Monotherapy in Quality of Life in Patients With Epilepsy

Uploaded by

Copyright:

Available Formats

Home

IMPACT OF LEVETIRACETAM AND VALPROIC MONOTHERAPY IN

You might also like